This paper contributes to the field of RNA vaccinology, specifically addressing a key challenge in self-amplifying RNA (saRNA) vaccine development. While saRNA vaccines offer advantages over conventional mRNA platforms by providing longer-lasting protection at lower doses, they also trigger undesirable side effects at protective doses. These side effects stem from excessive innate immune activation driven by double-stranded RNA intermediates generated during self-replication.

Excited to announce that PreciGenome will be exhibiting at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) in New Orleans, May 13-17, 2025! Join us at Booth #1818 to discover our latest innovations in: Lipid Nanoparticle (LNP) Synthesis Systems: Experience our NanoGenerator™ platform, designed for scalable, reproducible, and cost-effective LNP, liposome, and PLGA nanoparticle production-ideal for applications from early discovery to GMP manufact

Sanofi: Published research in Nanoscale on optimizing PEGylated lipids for enhanced mRNA delivery efficacy and stability. University of

Serina Therapeutics: Presented preclinical data on non-immunogenic POZ-lipid technology at the ACS Spring 2025 Meeting. Genevant Sciences an

This paper falls within the fields of medical mycology, immunology, and vaccinology, specifically addressing the emerging application of mRN

DOTMA vs. DOTAP lipid nanoparticles for GFP expression on human PBMCs and THP-1 cell line Authors:  Erwin Pavel Lamparelli, Elena...

This paper sits at the intersection of pharmaceutical technology, nanomedicine, and RNA therapeutics – fields that have gained tremendous at